Cathie Wood’s Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street Thinks
Tempus AI Inc. (NASDAQ:TEM) investors have a decision to make. Shares of the precision medicine company fell nearly 6% Monday, taking year-to-date losses to 16%, after it announced a $1.5 billion all-stock acquisition of Personalis, Inc. (NASDAQ:PSNL) — a deal that expands its oncology platform but also raises concerns about shareholder dilution ahead of earnings on July 30.
The selloff has made one of Cathie Wood‘s highest-conviction holdings considerably cheaper. The question now is whether the decline represents a buying opportunity—or a warning sign.
Cathie Wood and Wall Street Still Believe
Despite Monday’s weakness, Tempus remains the fourth-largest holding in the ARK Innovation ETF (BATS:ARKK), accounting for roughly 5.5% of the portfolio behind only Tesla, Inc. (NASDAQ:TSLA), Advanced Micro Devices, Inc. (NASDAQ:AMD) and Robinhood Markets, Inc. (NASDAQ:HOOD).
Wall Street also remains firmly bullish.
According to consensus estimates from 19 analysts, Tempus carries an average price target of $66.50, implying roughly 37% upside from current levels. The three most recent analyst updates—from Guggenheim, Freedom Capital Markets and Needham—average $66.33, suggesting analysts have yet to meaningfully lower expectations despite the recent pullback.
That suggests the market’s reaction is centered more on the timing and structure of the Personalis acquisition than on Tempus’ long-term AI and precision medicine strategy.
TEM Stock Chart Says Something Different
Chart created using Benzinga Pro
The technical picture, however, has deteriorated.
Tempus shares are now trading below their eight-day, 20-day and 50-day simple moving averages, a sign that short- and intermediate-term momentum has turned negative.
The stock’s MACD (moving average convergence/divergence) has produced a bearish crossover, with the histogram continuing to weaken, indicating downside momentum remains in control.
Meanwhile, the Relative Strength Index (RSI) has slipped to around 40. While the reading isn’t yet in oversold territory, it suggests buying momentum has faded considerably as sellers continue to dominate trading.
Taken together, the chart suggests investors may not yet be finished digesting the recent selloff.
So, Should Investors Buy the Dip?
The answer depends on which signal investors trust more.
Fundamentally, Tempus still enjoys strong support from both Wall Street analysts and Cathie Wood, whose flagship ETF continues to maintain the company as one of its largest positions. The Personalis acquisition also strengthens Tempus’s leadership in AI-powered precision oncology, even if investors are questioning the near-term impact of issuing stock to finance the deal.
Technically, however, the picture remains far less encouraging. Momentum indicators continue to point lower, and the stock has yet to show signs that buyers are stepping back in.
For investors looking to initiate or add to a position, the coming earnings report on July 30 could become the next major catalyst. Strong results—or a clearer roadmap for integrating Personalis while improving margins—could validate Wall Street’s optimism.
Until then, Tempus presents investors with a familiar dilemma: a company that analysts continue to like, a high-profile backer that hasn’t wavered, and a chart that still says patience may be the better trade.
Image via Shutterstock